Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Tivantinib||ARQ197|ARQ 197|ARQ-197||MET Inhibitor 53||Tivantinib (ARQ197) is a selective MET inhibitor, which may induce cell death in tumor cells overexpressing MET, although the antimitotic effect may be more responsible for the anti-tumor activity (PMID: 28246274, PMID: 32569187, PMID: 32073648).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||no benefit||Tivantinib||Phase II||Actionable||In a Phase II trial, Tivantinib (ARQ197) treatment only resulted in stable disease in 36% (4/11) of patients with relapsed or refractory multiple myeloma (PMID: 28337527).||28337527|
|Unknown unknown||stomach carcinoma||not applicable||Tivantinib||Phase II||Actionable||In a Phase II trial, Tivantinib (ARQ197) demonstrated efficacy in previously treated patients with metastatic gastric cancer (PMID: 24337769).||24337769|
|Unknown unknown||Advanced Solid Tumor||not applicable||Tivantinib||Phase I||Actionable||In a Phase I trial, Tivantinib (ARQ 197) demonstrated safety and some anti-tumor activity in patients with advanced solid tumors (PMID: 21976535).||21976535|
|Unknown unknown||alveolar soft part sarcoma||not applicable||Tivantinib||Phase II||Actionable||In a Phase II trial, tivantinib resulted in modest activity, in which 27 patients with alveolar soft part sarcoma had a median PFS of 5.5 months (PMID: 22605650).||22605650|
|Unknown unknown||renal cell carcinoma||not applicable||Tivantinib||Phase II||Actionable||In a Phase II trial, tivantinib resulted in modest activity in which six patients with renal cell carcinoma had a median PFS of 1.9 months (PMID: 22605650).||22605650|
|Unknown unknown||clear cell sarcoma||not applicable||Tivantinib||Phase II||Actionable||In a Phase II trial, tivantinib resulted in modest activity, in which 11 patients with clear cell sarcoma had a median PFS of 1.9 months (PMID: 22605650).||22605650|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02150733||Phase I||Tivantinib||Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment||Completed||USA||0|
|NCT01468922||Phase I||Tivantinib Pazopanib||Pazopanib and ARQ 197 for Advanced Solid Tumors||Completed||USA||0|
|NCT01755767||Phase III||Tivantinib||Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy||Completed||USA | CAN||14|